The application of Russell and Burch 3R principle in rodent models of neurodegenerative disease: The case of Parkinson's disease

Neuroscience and Biobehavioral Reviews

Volumn 33, Issue 1, 2009, Pages 18-32

  Manciocco, Arianna ^a   Chiarotti, Flavia ^a   Vitale, Augusto ^a   Calamandrei, Gemma ^a   Laviola, Giovanni ^a   Alleva, Enrico ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Animal welfare; Bioethics; Parkinson's disease; Rodent models

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; OXIDOPAMINE; ROTENONE;

ANIMAL MODEL; BIOETHICS; CHEMICAL MODEL; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; EXPERIMENTAL ANIMAL WELFARE; GENETIC MODEL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION; TRANSGENIC MOUSE;

ANIMAL EXPERIMENTATION; ANIMAL RIGHTS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NEURODEGENERATIVE DISEASES; RESEARCH; RODENTIA;

EID: 54049135958     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2008.08.002     Document Type: Review

References (177)

1. Al-Jarrah M., Pothakos K., Novikova L., Smirnova I.V., Kurz M.J., Stehno-Bittel L., and Lau Y.S. Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of Parkinsonism with severe neurodegeneration. Neuroscience 149 (2007) 28-37
2. Archibald F.S., and Tyree C. Manganese poisoning and the attack of trivalent manganese upon catecholamines. Arch. Biochem. Biophys. 256 (1987) 638-650
3. Aschner M., Erikson K.M., and Dorman D.C. Manganese dosimetry: species differences and implications for neurotoxicity. Crit. Rev. Toxicol. 35 (2005) 1-32
4. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., and Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295 (2002) 865-868
5. Balcome J.P. Laboratory environments and rodents' behavioural needs: a review. Lab. Anim. 40 (2006) 217-235
6. Ballard P.A., Tetrud J.W., and Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985) 949-956
7. Barneoud P., Parmentier S., Mazadier M., Miquet J.M., Boireau A., Dubedat P., and Blanchard J.C. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neuroscience 67 (1995) 837-848
8. Bateson P. When to experiment on animals. New Sci. 109 (1986) 30-32
9. Bateson P. Assessment of pain in animals. Anim. Behav. 42 (1991) 827-839
10. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2 (2001) 325-334
11. Betarbet R., Sherer T.B., Di Monte D.A., and Greenamyre J.T. Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol. 12 (2002) 499-510
12. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
13. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
14. Blanchard V., Anglade P., Dziewczapolski G., Savasta M., Agid Y., and Raisman-Vozari R. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res. 709 (1996) 319-325
15. Branchi I., and Ricceri L. Refining learning and memory assessment in laboratory rodents. An ethological perspective. Ann. Ist. Super Sanita. 40 (2004) 231-236
16. Broussolle E., and Thobois S. Genetics and environmental factors of Parkinson disease. Rev. Neurol. (Paris) 158 Spec. no. 1 (2002) S11-S23
17. Brown M.J., and Murray K.A. Phenotyping of genetically engineered mice: humane, ethical, environmental, and husbandry issues. Ilar J. 47 (2006) 118-123
18. Buchanan-Smith H.M., Renne A.E., Vitale A., Pollo S., Prescott M.J., and Morton D.B. Harmonising the definition of refinement. Anim. Welf. 14 (2005) 379-384
19. Burgdorf J., and Panksepp J. Tickling induces reward in adolescent rats. Physiol. Behav. 72 (2001) 167-173
20. Calamandrei G. Ethological and methodological considerations in the use of newborn rodents in biomedical research. Ann. Ist Super Sanita. 40 (2004) 195-200
21. Callier S., Morissette M., Grandbois M., and Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 37 (2000) 245-251
22. Callio J., Oury T.D., and Chu C.T. Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. J. Biol. Chem. 280 (2005) 18536-18542
23. Carli M., Evenden J.L., and Robbins T.W. Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention. Nature 313 (1985) 679-682
24. Carlsson A., Lindqvist M., and Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180 (1957) 1200
25. (CEC), C. o. E.C., 1986. Council Directive on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purpose), no. 86/609/ECC.
26. (CEC), C. o. t. E. C., 2007. Commission Recommendation of 18 June 2007 on guidelines for the accommodation and care of animals used for experimental and other scientific purposes (notified under document number C(2007)2525. In: Official Journale of the European Union), vol. Volume 50, 30 July 2007, no. 2007/526/EC.
27. Chang J.W., Wachtel S.R., Young D., and Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88 (1999) 617-628
28. Chesler E.J., Wilson S.G., Lariviere W.R., Rodriguez-Zas S.L., and Mogil J.S. Influences of laboratory environment on behavior. Nat. Neurosci. 5 (2002) 1101-1102
29. Chiarotti F., Alleva E., and Bignami G. Problems of test choice and data analysis in behavioral teratology: the case of prenatal benzodiazepines. Neurotoxicol. Teratol. 9 (1987) 179-186
30. Coecke S., Goldberg A.M., Allen S., Buzanska L., Calamandrei G., Crofton K., Hareng L., Hartung T., Knaut H., Honegger P., Jacobs M., Lein P., Li A., Mundy W., Owen D., Schneider S., Silbergeld E., Reum T., Trnovec T., Monnet-Tschudi F., and Bal-Price A. Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Environ. Health Perspect. 115 (2007) 924-931
31. Cohen J. Statistical Power Analysis for the Behavioural Sciences (1988), Lawrence Erlbaum, Hillsdale
32. Colebrooke R.E., Humby T., Lynch P.J., McGowan D.P., Xia J., and Emson P.C. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur. J. Neurosci. 24 (2006) 2622-2630
33. Collier T.J., Sortwell C.E., and Daley B.F. Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation. J. Neurosci. 19 (1999) 5563-5573
34. Connor B., Kozlowski D., Schallert T., Tillerson J.L., Davidson B.L., and Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6 (1996) 1936-1951
35. Cousins M.S., and Salamone J.D. Involvement of ventrolateral striatal dopamine in movement initiation and execution: a microdialysis and behavioral investigation. Neuroscience 70 (1996) 849-859
36. Cummings J.L. Depression and Parkinson's disease: a review. Am. J. Psychiatry 149 (1992) 443-454
37. Date I., Felten D.L., and Felten S.Y. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 519 (1990) 266-276
38. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
39. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., and Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1 (1979) 249-254
40. Dawson T.M. Parkin and defective ubiquitination in Parkinson's disease. J. Neural. Transm. Suppl. (2006) 209-213
41. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 (2002) 303-317
42. Dluzen D.E., McDermott J.L., and Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol. Teratol. 18 (1996) 603-606
43. Dunnett S.B., and Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (1999) A32-A39
44. Ehninger D., and Kempermann G. Regional effects of wheel running and environmental enrichment on cell genesis and microglia proliferation in the adult murine neocortex. Cereb. Cortex 13 (2003) 845-851
45. Emborg M.E. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods 139 (2004) 121-143
46. Engele J., and Bohn M.C. The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia. J. Neurosci. 11 (1991) 3070-3078
47. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
48. Fernagut P.O., and Chesselet M.F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 17 (2004) 123-130
49. Festing M.F., and Altman D.G. Guidelines for the design and statistical analysis of experiments using laboratory animals. Ilar J. 43 (2002) 244-258
50. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., and Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24 (2004) 9434-9440
51. Fleming S.M., Delville Y., and Schallert T. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Behav. Brain Res. 156 (2005) 201-213
52. Fleming S.M., Fernagut P.O., and Chesselet M.F. Genetic mouse models of Parkinsonism: strengths and limitations. NeuroRx 2 (2005) 495-503
53. Fleming S.M., Salcedo J., Hutson C.B., Rockenstein E., Masliah E., Levine M.S., and Chesselet M.F. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 142 (2006) 1245-1253
54. Gal S., Fridkin M., Amit T., Zheng H., and Youdim M.B. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J. Neural. Transm. Suppl. (2006) 447-456
55. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma J.F.J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
56. Gerlach M., and Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural. Transm. 103 (1996) 987-1041
57. Glenn L.M. When pigs fly? Legal and ethical issues in transgenics and the creation of chimera. The Walter C. Randall Biomedical Ethics lecture. Physiologist 46 (2003) 251
58. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., and Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 (1998) 1346-1350
59. Haemisch A., Voss T., and Gartner K. Effects of environmental enrichment on aggressive behavior, dominance hierarchies, and endocrine states in male DBA/2J mice. Physiol. Behav. 56 (1994) 1041-1048
60. Hashimoto M., Rockenstein E., and Masliah E. Transgenic models of alpha-synuclein pathology: past, present, and future. Ann. N. Y. Acad. Sci. 991 (2003) 171-188
61. Hawkins P. Recognizing and assessing pain, suffering and distress in laboratory animals: a survey of current practice in the UK with recommendations. Lab. Anim. 36 (2002) 378-395
62. Hirsch E.C. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment. Ann. Neurol. 47 (2000) S115-S120 (discussion S120-S111)
63. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., and Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51 (2002) 235-242
64. Hornykiewicz O., Kish S.J., Becker L.E., Farley I., and Shannak K. Brain neurotransmitters in dystonia musculorum deformans. N. Engl. J. Med. 315 (1986) 347-353
65. Howells F.M., Russell V.A., Mabandla M.V., and Kellaway L.A. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease. Behav. Brain. Res. 165 (2005) 210-220
66. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., and Masliah E. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157 (2000) 401-410
67. Huang J., Liu H., Gu W., Yan Z., Xu Z., Yang Y., Zhu X., and Li Y. A delivery strategy for rotenone microspheres in an animal model of Parkinson's disease. Biomaterials 27 (2006) 937-946
68. Hurley L.S. The roles of trace elements in foetal and neonatal development. Philos. Trans. R Soc. Lond. B Biol. Sci. 294 (1981) 145-152
69. Hurst J.L., Barnard C.J., Hare R., Wheeldon E.B., and West C.D. Housing and welfare in laboratory rats: time-budgeting and pathophysiology in single-sex groups. Anim. Behav. 52 (1996) 335-360
70. Hurst J.L., Barnard C.J., Tolladay U., Nevision C.M., and West C.D. Housing and welfare in laboratory rats: effects of cage stocking density and behavioural predictors of welfare. Anim. Behav. 58 (1999) 563-586
71. Hussain S.M., Javorina A.K., Schrand A.M., Duhart H.M., Ali S.F., and Schlager J.J. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol. Sci. 92 (2006) 456-463
72. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., and Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
73. Jankowsky J.L., Savonenko A., Schilling G., Wang J., Xu G., and Borchelt D.R. Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr. Neurol. Neurosci. Rep. 2 (2002) 457-464
74. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat. Disord. 9 (2003) 131-137
75. Jennings M., Batchelor G.R., Brain P.F., Dick A., Elliott H., Francis R.J., Hubrecht R.C., Hurst J.L., Morton D.B., Peters A.G., Raymond R., Sales G.D., Sherwin C.M., and West C. Refining rodent husbandry: the mouse. Report of the Rodent Refinement Working Party. Lab. Anim. 32 (1998) 233-259
76. Jeyasingham R.A., Baird A.L., Meldrum A., and Dunnett S.B. Differential effects of unilateral striatal and nigrostriatal lesions on grip strength, skilled paw reaching and drug-induced rotation in the rat. Brain Res. Bull. 55 (2001) 541-548
77. Kaakkola S., and Teravainen H. Animal models of parkinsonism. Pharmacol. Toxicol. 67 (1990) 95-100
78. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
79. Kitamura Y., Inden M., Sanada H., Takata K., Taniguchi T., Shimohama S., Orii H., Mochii M., Agata K., and Watanabe K. Inhibitory effects of antiparkinsonian drugs and caspase inhibitors in a parkinsonian flatworm model. J. Pharmacol. Sci. 92 (2003) 137-142
80. Kitamura Y., Shimohama S., Akaike A., and Taniguchi T. The parkinsonian models: invertebrates to mammals. Jpn. J. Pharmacol. 84 (2000) 237-243
81. Kitamura Y., Taniguchi T., Shimohama S., Akaike A., and Nomura Y. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem. Res. 28 (2003) 1035-1040
82. Knutson B., Burgdorf J., and Panksepp J. Anticipation of play elicits high-frequency ultrasonic vocalizations in young rats. J. Comp. Psychol. 112 (1998) 65-73
83. Kobayashi S., Ohashi Y., and Ando S. Effects of enriched environments with different durations and starting times on learning capacity during aging in rats assessed by a refined procedure of the Hebb-Williams maze task. J. Neurosci. Res. 70 (2002) 340-346
84. Kopin I.J., and Markey S.P. MPTP toxicity: implications for research in Parkinson's disease. Annu. Rev. Neurosci. 11 (1988) 81-96
85. Krieglstein K., Henheik P., Farkas L., Jaszai J., Galter D., Krohn K., and Unsicker K. Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons. J. Neurosci. 18 (1998) 9822-9834
86. Kuhn K., Wellen J., Link N., Maskri L., Lubbert H., and Stichel C.C. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 17 (2003) 1-12
87. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
88. Laviola G., Hannan A.J., Macrì S., Solinas M., and Jaber M. Effects of enriched environment on animal models of neurodegenerative disease and psychiatric disorders. Neurobiol. Dis. 31 (2008) 159-168
89. Lee C.S., Sauer H., and Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience 72 (1996) 641-653
90. Lee M., Hyun D., Halliwell B., and Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76 (2001) 998-1009
91. Lermontova N., Drany O., Dobrota D., Mezesova V., Lombardi V., and Bachurin S. Relative resistance of rabbits to MPTP neurotoxicity. Mol. Chem. Neuropathol. 25 (1995) 135-141
92. Lindner M.D., Cain C.K., Plone M.A., Frydel B.R., Blaney T.J., Emerich D.F., and Hoane M.R. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav. Brain Res. 102 (1999) 1-16
93. Lindner M.D., Plone M.A., Francis J.M., Blaney T.J., Salamone J.D., and Emerich D.F. Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task. Behav. Brain Res. 86 (1997) 25-40
94. Loew F.M. Beyond transgenics: ethics and values. Br. Vet. J. 150 (1994) 3-5
95. Mabandla M., Kellaway L., St Clair Gibson A., and Russell V.A. Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle. Metab. Brain Dis. 19 (2004) 43-50
96. Machin D., and Campbell M. Statisticals Tables for the Design of Clinical Trials (1987), Blackwell Scientific Publications, Oxford
97. Manser C.E., Broom D.M., Overend P., and Morris T.H. Investigations into the preferences of laboratory rats for nest-boxes and nesting materials. Lab. Anim. 32 (1998) 23-35
98. Marashi V., Barnekow A., Ossendorf E., and Sachser N. Effects of different forms of environmental enrichment on behavioral, endocrinological, and immunological parameters in male mice. Horm. Behav. 43 (2003) 281-292
99. Match M., Schwarz R., and Ellgring H. Patterns of psychological problems in Parkinson's disease. Acta Neurol. Scand. 111 (2005) 95-101
100. McConway K. The number of subjects in animal behaviour experiments: is still right?. Anim. Behav. Suppl. (1992) 35-38
101. Menegon A., Board P.G., Blackburn A.C., Mellick G.D., and Le Couteur D.G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352 (1998) 1344-1346
102. Mertens C., and Rulicke T. A comprehensive form for the standardized characterization of transgenic rodents: genotype, phenotype, welfare assessment, recommendations for refinement. Altex 17 (2000) 15-21
103. Miller D.B., Ali S.F., O'Callaghan J.P., and Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. N. Y. Acad. Sci. 844 (1998) 153-165
104. Moore C.J., and Mepham T.B. Transgenesis and animal welfare. Altern. Lab. Anim. 23 (1995) 380-397
105. Morris R.G.M. Spatial localization does not require the presence of local cues. Learn. Motiv. 12 (1981) 239-260
106. Morton D.B., and Griffiths P.H. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. Vet. Rec. 116 (1985) 431-436
107. Murase S., and McKay R.D. A specific survival response in dopamine neurons at most risk in Parkinson's disease. J Neurosci. 26 (2006) 9750-9760
108. Nagy A., Gertsenstein M., Vintersten K., and Behringer R. Manipulating the Mouse Embryo: A Laboratory Manual (2003), Cold Spring Harbour Laboratory Press, New York
109. Nyberg P., Nordberg A., Wester P., and Winblad B. Dopaminergic deficiency is more pronounced in putamen than in nucleus caudatus in Parkinson's patients. Neurochem. Pathol. 1 (1983) 193-202
110. O'Dell L.E., Chen S.A., Smith R.T., Specio S.E., Balster R.L., Paterson N.E., Markou A., Zorrilla E.P., and Koob G.F. Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats. J. Pharmacol. Exp. Ther. 320 (2007) 180-193
111. Ohashi S., Mori A., Kurihara N., Mitsumoto Y., and Nakai M. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neurosci. Lett. 401 (2006) 183-187
112. Olsson I.A., and Dahlborn K. Improving housing conditions for laboratory mice: a review of "environmental enrichment". Lab. Anim. 36 (2002) 243-270
113. Olsson M., Nikkhah G., Bentlage C., and Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15 (1995) 3863-3875
114. Otto D., and Unsicker K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J. Neurosci. 10 (1990) 1912-1921
115. Passineau M.J., Green E.J., and Dietrich W.D. Therapeutic effects of environmental enrichment on cognitive function and tissue integrity following severe traumatic brain injury in rats. Exp. Neurol. 168 (2001) 373-384
116. Patterson-Kane E.G. Cage size preference in rats in the laboratory. J. Appl. Anim. Welf. Sci. 5 (2002) 63-72
117. Patterson-Kane E.G., Hunt M., and Harper D. Rats demand social contact. Anim. Welf. 11 (2002) 327-332
118. Patterson-Kane E.G., Hunt M., and Harper D.N. Behavioral indexes of poor welfare in laboratory rats. J. Appl. Anim. Welf. Sci. 2 (1999) 97-110
119. Paylor R., Morrison S.K., Rudy J.W., Waltrip L.T., and Wehner J.M. Brief exposure to an enriched environment improves performance on the Morris water task and increases hippocampal cytosolic protein kinase C activity in young rats. Behav. Brain Res. 52 (1992) 49-59
120. Perese D.A., Ulman J., Viola J., Ewing S.E., and Bankiewicz K.S. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res. 494 (1989) 285-293
121. Polites H.G., and Pinkert C.A. Transgenic Animal Production Focusing in the Mouse Model (2002), Academic Press, San Diego
122. Poole T. Happy animals make good science. Lab. Anim. 31 (1997) 116-124
123. Porter D.G. Ethical scores for animal experiments. Nature 356 (1992) 101-102
124. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., and Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
125. Puopolo M., Santucci D., Chiarotti F., and Alleva E. Behavioural effects of endocrine disrupting chemicals on laboratory rodents: statistical methodologies and an application concerning developmental PCB exposure. Chemosphere 39 (1999) 1259-1271
126. Renner M.J., and Rosenzweig M.R. Enriched and Impoverished Environments: Effects on Brain and Behaviour (1987), Springer-Verlag, New York, NY
127. Rockenstein E., Crews L., and Masliah E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv. Drug Deliv. Rev. 59 (2007) 1093-1102
128. Russell, W.M.S., Burch, R.L., 1959, reprinted 1992. The Principles of Humane Experimental Technique. Universities Federation for Animal Welfare, Wheathampstaed, UK.
129. Sabol K.E., Neill D.B., Wages S.A., Church W.H., and Justice J.B. Dopamine depletion in a striatal subregion disrupts performance of a skilled motor task in the rat. Brain Res. 335 (1985) 33-43
130. Sang T.K., and Jackson G.R. Drosophila models of neurodegenerative disease. NeuroRx 2 (2005) 438-446
131. Schneider J.S., and Markham C.H. Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry. Brain Res. 373 (1986) 258-267
132. Schuster S., Nadjar A., Guo J.T., Li Q., Ittrich C., Hengerer B., and Bezard E. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of l-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J. Neurosci. 28 (2008) 4311-4316
133. Sedelis M., Schwarting R.K., and Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001) 109-125
134. Sgado P., Alberi L., Gherbassi D., Galasso S.L., Ramakers G.M., Alavian K.N., Smidt M.P., Dyck R.H., and Simon H.H. Slow progressive degeneration of nigral dopaminergic neurons in postnatal Engrailed mutant mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15242-15247
135. Sharp J.L., Zammit T.G., Azar T.A., and Lawson D.M. Stress-like responses to common procedures in male rats housed alone or with other rats. Contemp. Top Lab. Anim. Sci. 41 (2002) 8-14
136. Sherer T.B., Betarbet R., and Greenamyre J.T. Pathogenesis of Parkinson's disease. Curr. Opin. Invest. Drugs 2 (2001) 657-662
137. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
138. Sherwin C.M. Comfortable Quarters for Mice in Research Institutions (2002), Animal Welfare Institute, Washington, DC
139. Sherwin C.M., and Olsson I.A. Housing conditions affect self-administration of anxiolytic by laboratory mice. Anim. Welf. 13 (2004) 33-39
140. Shults C.W., Ray J., Tsuboi K., and Gage F.H. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine. Brain Res. 883 (2000) 192-204
141. Snyder A.M., Stricker E.M., and Zigmond M.J. Stress-induced neurological impairments in an animal model of Parkinsonism. Ann. Neurol. 18 (1985) 544-551
142. Sortwell C.E., Camargo M.D., Pitzer M.R., Gyawali S., and Collier T.J. Diminished survival of mesencephalic dopamine neurons grafted into aged hosts occurs during the immediate postgrafting interval. Exp. Neurol. 169 (2001) 23-29
143. Speciale S.G. MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol. Teratol. 24 (2002) 607-620
144. Spirduso W.W., Gilliam P.E., Schallert T., Upchurch M., Vaughn D.M., and Wilcox R.E. Reactive capacity: a sensitive behavioral marker of movement initiation and nigrostriatal dopamine function. Brain Res. 335 (1985) 45-54
145. Stasiak K.L., Maul D., French E., Hellyer P.W., and VandeWoude S. Species-specific assessment of pain in laboratory animals. Contemp. Top Lab. Anim. Sci. 42 (2003) 13-20
146. Still A.W. On the number of subjects used in animal behaviour experiments. Anim. Behav. 30 (1982) 873-880
147. Stryer L. Biochemistry (1999), WH Freeman and Company, New York
148. Szekely B.C., Kosanovich N.N., and Sheppard W. Adjunctive treatment in Parkinson's disease: physical therapy and comprehensive group therapy. Rehabil. Lit. 43 (1982) 72-76
149. Tamas A., Lubics A., Szalontay L., Lengvari I., and Reglodi D. Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Behav. Brain Res. 158 (2005) 221-229
150. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 119 (2003) 899-911
151. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., and Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21 (2001) 4427-4435
152. Townsend P. Use of in-cage shelters by laboratory rats. Anim. Welf. 6 (1997) 95-103
153. Trojanowski J.Q., and Lee V.M. Transgenic models of tauopathies and synucleinopathies. Brain Pathol. 9 (1999) 733-739
154. Turner C.A., Yang M.C., and Lewis M.H. Environmental enrichment: effects on stereotyped behavior and regional neuronal metabolic activity. Brain Res. 938 (2002) 15-21
155. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367 (1971) 95-122
156. United States Department of Agriculture, 1990. Animal Welfare Act. In: United States Code, vol. 7.
157. Van de Weerd H.A., Baumans V., Koolhaas J.M., and Van Zutphen L.F.M. Strain specific behavioural response to environmental enrichment in the mouse. J. Exp. Anim. Sci. 36 (1994) 117-127
158. Van de Weerd H.A., Van Loo P.L.P., Van Zutphen L.F.M., Koolhaas J.M., and Baumans V. Nesting material as environmental enrichment has no adverse effects on behaviour and physiology of laboratory mice. Physiol. Behav. 62 (1997) 1019-1028
159. Van den Berg C.L., Pijlman F.T., Koning H.A., Diergaarde L., Van Ree J.M., and Spruijt B.M. Isolation changes the incentive value of sucrose and social behaviour in juvenile and adult rats. Behav. Brain Res. 106 (1999) 133-142
160. Van der Harst J.E., Fermont P.C.J., Bilstra A.E., and Spruijt B.M. Access to enriched housing is rewarding to rats as reflected by their anticipatory behaviour. Anim. Behav. 66 (1999) 493-504
161. Van Driel K.S., and Talling J.C. Familiarity increases consistency in animal tests. Behav. Brain Res. 159 (2005) 243-245
162. Van Loo P.L.P., de Groot A.C., Van Zutphen B.F.M., and Baumans V. Do male mice prefer or avoid each other's company? Influence of hierarchy, kinship, and familiarity. J. Appl Anim. Welf. Sci. 4 (2001) 91-103
163. Van Oosten R.V., and Cools A.R. Functional updating of the bilateral 6-OHDA rat model for Parkinson's disease. Soc. Neurosci. 25 (1999) 1599
164. Vitale, A., et al., 2008. The 3R principle and the use of non-human primates in the study of neurodegenerative diseases: The case of Parkinson's disease. Neurosci. Biobehav. Rev. doi:10.1016/i.neubiorev.2008.08.006.
165. Wang Y., Hamburger M., Cheng C.H.K., Costall B., Naylor R.J., Jenner P., and Hostettman K. Neurotoxic sesquiterpenoids from the yellow star thistle Centaurea solstitialis L. (Asteraceae). Helv. Chim. Acta 74 (1991) 117-123
166. Wetherill G.B. Sequential Methods in Statistics (1976), Methuen, London
167. Whishaw I.Q., O'Connor W.T., and Dunnett S.B. Disruption of central cholinergic systems in the rat by basal forebrain lesions or atropine: effects on feeding, sensorimotor behaviour, locomotor activity and spatial navigation. Behav. Brain Res. 17 (1985) 103-115
168. Williams-Gray C.H., Foltynie T., Lewis S.J., and Barker R.A. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 20 (2006) 477-505
169. Winkler C., Kirik D., Bjorklund A., and Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10 (2002) 165-186
170. Wolfer D.P., Litvin O., Morf S., Nitsch R.M., Lipp H.P., and Wurbel H. Laboratory animal welfare: cage enrichment and mouse behaviour. Nature 432 (2004) 821-822
171. Wolfle T.L. Introduction: environmental enrichment. Ilar J. 46 (2005) 79-82
172. Woodcock E.A., and Richardson R. Effects of environmental enrichment on rate of contextual processing and discriminative ability in adult rats. Neurobiol. Learn. Mem. 73 (2000) 1-10
173. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., and Patrie J. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psychiatry 75 (2004) 637-639
174. Wurbel H. Ideal homes? Housing effects on rodent brain and behaviour. Trends Neurosci. 24 (2001) 207-211
175. Wurbel H. Publications should include an animal-welfare section. Nature 446 (2007) 257
176. Zheng H., Gal S., Weiner L.M., Bar-Am O., Warshawsky A., Fridkin M., and Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95 (2005) 68-78
177. Zimmermann A., Stauffacher M., Langhans W., and Wurbel H. Enrichment-dependent differences in novelty exploration in rats can be explained by habituation. Behav. Brain Res. 121 (2001) 11-20